Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：124頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 16
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 18
Boehringer Ingelheim GmbH 18
AstraZeneca PLC 19
GlaxoSmithKline plc 20
Emergent BioSolutions Inc. 21
Infinity Pharmaceuticals, Inc. 22
Genmab A/S 23
Celgene Corporation 24
Portola Pharmaceuticals, Inc. 25
Pharmacyclics, Inc. 26
MorphoSys AG 27
Threshold Pharmaceuticals, Inc. 28
Noxxon Pharma AG 29
SBI Biotech Co., Ltd. 30
AbbVie Inc. 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ibrutinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ofatumumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
duvelisib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ABT-199 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
otlertuzumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NOX-A-12 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MOR-208 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
afuresertib - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
metformin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PRT-2070 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TH-302 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GNKG-168 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CC-292 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
BI-836826 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AZD-6738 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 79
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 112
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 113
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 114
Featured News & Press Releases 114
Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 114
Dec 09, 2013: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia 115
Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 116
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 116
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 117
Jun 19, 2013: Janssen Announces Publication Of Phase Ib/II Trial Data Of Ibrutinib In Relapsed Or Refractory Chronic Lymphocytic Leukemia In The New England Journal Of Medicine 118
Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting 119
Jun 17, 2013: TG Therapeutics Presents Clinical Poster Presentations On TG-1101 At EHA Meeting 121
May 15, 2013: Onyx Pharma To Present Data On Kyprolis At 49th American Society Of Clinical Oncology Annual Meeting 121
Mar 25, 2013: Genmab And GSK Announce Japanese Approval Of Leukemia Drug Arzerra 122
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 124
Disclaimer 124
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 18
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca PLC, H1 2014 19
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline plc, H1 2014 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2014 21
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 22
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2014 23
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2014 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2014 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2014 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Noxxon Pharma AG, H1 2014 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by SBI Biotech Co., Ltd., H1 2014 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2014 31
Assessment by Monotherapy Products, H1 2014 32
Number of Products by Stage and Target, H1 2014 35
Number of Products by Stage and Mechanism of Action, H1 2014 38
Number of Products by Stage and Route of Administration, H1 2014 40
Number of Products by Stage and Molecule Type, H1 2014 42
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2014 79
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2014 112
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2014 113
List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Assessment by Monotherapy Products, H1 2014 32
Number of Products by Top 10 Target, H1 2014 33
Number of Products by Stage and Top 10 Target, H1 2014 34
Number of Products by Top 10 Mechanism of Action, H1 2014 36
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 37
Number of Products by Top 10 Route of Administration, H1 2014 39
Number of Products by Stage and Top 10 Route of Administration, H1 2014 40
Number of Products by Top 10 Molecule Type, H1 2014 41
Number of Products by Stage and Top 10 Molecule Type, H1 2014 42
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 16
Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 18
Boehringer Ingelheim GmbH 18
AstraZeneca PLC 19
GlaxoSmithKline plc 20
Emergent BioSolutions Inc. 21
Infinity Pharmaceuticals, Inc. 22
Genmab A/S 23
Celgene Corporation 24
Portola Pharmaceuticals, Inc. 25
Pharmacyclics, Inc. 26
MorphoSys AG 27
Threshold Pharmaceuticals, Inc. 28
Noxxon Pharma AG 29
SBI Biotech Co., Ltd. 30
AbbVie Inc. 31
Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
ibrutinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ofatumumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
duvelisib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ABT-199 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
otlertuzumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NOX-A-12 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MOR-208 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
afuresertib - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
metformin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PRT-2070 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
TH-302 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GNKG-168 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CC-292 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
BI-836826 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AZD-6738 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 79
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 112
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 113
Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 114
Featured News & Press Releases 114
Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 114
Dec 09, 2013: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia 115
Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 116
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 116
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 117
Jun 19, 2013: Janssen Announces Publication Of Phase Ib/II Trial Data Of Ibrutinib In Relapsed Or Refractory Chronic Lymphocytic Leukemia In The New England Journal Of Medicine 118
Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting 119
Jun 17, 2013: TG Therapeutics Presents Clinical Poster Presentations On TG-1101 At EHA Meeting 121
May 15, 2013: Onyx Pharma To Present Data On Kyprolis At 49th American Society Of Clinical Oncology Annual Meeting 121
Mar 25, 2013: Genmab And GSK Announce Japanese Approval Of Leukemia Drug Arzerra 122
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 124
Disclaimer 124
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 18
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca PLC, H1 2014 19
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline plc, H1 2014 20
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2014 21
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 22
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2014 23
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2014 24
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 25
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2014 26
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2014 27
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 28
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Noxxon Pharma AG, H1 2014 29
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by SBI Biotech Co., Ltd., H1 2014 30
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2014 31
Assessment by Monotherapy Products, H1 2014 32
Number of Products by Stage and Target, H1 2014 35
Number of Products by Stage and Mechanism of Action, H1 2014 38
Number of Products by Stage and Route of Administration, H1 2014 40
Number of Products by Stage and Molecule Type, H1 2014 42
Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2014 79
Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2014 112
Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2014 113
List of Figures
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Assessment by Monotherapy Products, H1 2014 32
Number of Products by Top 10 Target, H1 2014 33
Number of Products by Stage and Top 10 Target, H1 2014 34
Number of Products by Top 10 Mechanism of Action, H1 2014 36
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 37
Number of Products by Top 10 Route of Administration, H1 2014 39
Number of Products by Stage and Top 10 Route of Administration, H1 2014 40
Number of Products by Top 10 Molecule Type, H1 2014 41
Number of Products by Stage and Top 10 Molecule Type, H1 2014 42
